vs
Side-by-side financial comparison of 4D Molecular Therapeutics, Inc. (FDMT) and IMAX CORP (IMAX). Click either name above to swap in a different company.
IMAX CORP is the larger business by last-quarter revenue ($125.2M vs $85.1M, roughly 1.5× 4D Molecular Therapeutics, Inc.). 4D Molecular Therapeutics, Inc. runs the higher net margin — 22.8% vs 0.5%, a 22.3% gap on every dollar of revenue. On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs 35.1%). 4D Molecular Therapeutics, Inc. produced more free cash flow last quarter ($28.5M vs $28.0M). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs 25.8%).
4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.
IMAX Corporation is a Canadian production theatre company which designs and manufactures IMAX cameras and projection systems as well as performing film development, production, post-production and distribution to IMAX-affiliated theatres worldwide. Founded in Montreal in 1967, it has headquarters in the Toronto area, and operations in New York City and Los Angeles.
FDMT vs IMAX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $85.1M | $125.2M |
| Net Profit | $19.4M | $637.0K |
| Gross Margin | — | 57.6% |
| Operating Margin | 17.3% | 19.3% |
| Net Margin | 22.8% | 0.5% |
| Revenue YoY | 8508900.0% | 35.1% |
| Net Profit YoY | 139.1% | -88.0% |
| EPS (diluted) | $0.43 | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $85.1M | $125.2M | ||
| Q3 25 | $90.0K | $106.7M | ||
| Q2 25 | $15.0K | $91.7M | ||
| Q1 25 | $14.0K | $86.7M | ||
| Q4 24 | $1.0K | $92.7M | ||
| Q3 24 | $3.0K | $91.5M | ||
| Q2 24 | $5.0K | $89.0M | ||
| Q1 24 | $28.0K | $79.1M |
| Q4 25 | $19.4M | $637.0K | ||
| Q3 25 | $-56.9M | $20.7M | ||
| Q2 25 | $-54.7M | $11.3M | ||
| Q1 25 | $-48.0M | $2.3M | ||
| Q4 24 | — | $5.3M | ||
| Q3 24 | $-43.8M | $13.9M | ||
| Q2 24 | $-35.0M | $3.6M | ||
| Q1 24 | $-32.4M | $3.3M |
| Q4 25 | — | 57.6% | ||
| Q3 25 | — | 63.1% | ||
| Q2 25 | — | 58.5% | ||
| Q1 25 | — | 61.4% | ||
| Q4 24 | — | 52.2% | ||
| Q3 24 | — | 55.8% | ||
| Q2 24 | — | 49.4% | ||
| Q1 24 | — | 59.3% |
| Q4 25 | 17.3% | 19.3% | ||
| Q3 25 | -67983.3% | 27.2% | ||
| Q2 25 | -396373.3% | 15.6% | ||
| Q1 25 | -383007.1% | 19.3% | ||
| Q4 24 | — | 10.3% | ||
| Q3 24 | -1704400.0% | 21.2% | ||
| Q2 24 | -849120.0% | 3.2% | ||
| Q1 24 | -136200.0% | 15.3% |
| Q4 25 | 22.8% | 0.5% | ||
| Q3 25 | -63195.6% | 19.4% | ||
| Q2 25 | -364386.7% | 12.3% | ||
| Q1 25 | -342657.1% | 2.7% | ||
| Q4 24 | — | 5.7% | ||
| Q3 24 | -1461433.3% | 15.2% | ||
| Q2 24 | -699060.0% | 4.0% | ||
| Q1 24 | -115717.9% | 4.1% |
| Q4 25 | $0.43 | $0.02 | ||
| Q3 25 | $-1.01 | $0.37 | ||
| Q2 25 | $-0.98 | $0.20 | ||
| Q1 25 | $-0.86 | $0.04 | ||
| Q4 24 | — | $0.09 | ||
| Q3 24 | $-0.79 | $0.26 | ||
| Q2 24 | $-0.63 | $0.07 | ||
| Q1 24 | $-0.66 | $0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $402.7M | $151.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $505.7M | $337.9M |
| Total Assets | $566.7M | $894.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $402.7M | $151.2M | ||
| Q3 25 | $305.1M | $143.1M | ||
| Q2 25 | $293.2M | $109.3M | ||
| Q1 25 | $321.4M | $97.1M | ||
| Q4 24 | $424.9M | $100.6M | ||
| Q3 24 | $501.9M | $104.5M | ||
| Q2 24 | $541.9M | $91.6M | ||
| Q1 24 | $525.9M | $81.0M |
| Q4 25 | $505.7M | $337.9M | ||
| Q3 25 | $369.0M | $349.5M | ||
| Q2 25 | $420.9M | $320.4M | ||
| Q1 25 | $469.7M | $299.5M | ||
| Q4 24 | $510.6M | $299.5M | ||
| Q3 24 | $552.9M | $289.4M | ||
| Q2 24 | $588.3M | $267.2M | ||
| Q1 24 | $600.6M | $258.8M |
| Q4 25 | $566.7M | $894.0M | ||
| Q3 25 | $424.0M | $889.6M | ||
| Q2 25 | $473.6M | $868.6M | ||
| Q1 25 | $515.7M | $848.3M | ||
| Q4 24 | $560.4M | $830.4M | ||
| Q3 24 | $604.0M | $847.6M | ||
| Q2 24 | $620.1M | $827.4M | ||
| Q1 24 | $629.9M | $824.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.6M | $29.4M |
| Free Cash FlowOCF − Capex | $28.5M | $28.0M |
| FCF MarginFCF / Revenue | 33.5% | 22.3% |
| Capex IntensityCapex / Revenue | 0.1% | 1.1% |
| Cash ConversionOCF / Net Profit | 1.47× | 46.11× |
| TTM Free Cash FlowTrailing 4 quarters | $-109.9M | $118.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.6M | $29.4M | ||
| Q3 25 | $-46.5M | $67.5M | ||
| Q2 25 | $-43.4M | $23.2M | ||
| Q1 25 | $-47.8M | $7.0M | ||
| Q4 24 | $-134.6M | $11.5M | ||
| Q3 24 | $-29.4M | $35.3M | ||
| Q2 24 | $-30.2M | $35.0M | ||
| Q1 24 | $-29.1M | $-11.0M |
| Q4 25 | $28.5M | $28.0M | ||
| Q3 25 | $-46.6M | $64.8M | ||
| Q2 25 | $-43.4M | $20.9M | ||
| Q1 25 | $-48.4M | $5.3M | ||
| Q4 24 | $-138.4M | $6.9M | ||
| Q3 24 | $-31.2M | $34.2M | ||
| Q2 24 | $-30.6M | $33.5M | ||
| Q1 24 | $-29.8M | $-12.1M |
| Q4 25 | 33.5% | 22.3% | ||
| Q3 25 | -51765.6% | 60.7% | ||
| Q2 25 | -289620.0% | 22.8% | ||
| Q1 25 | -345635.7% | 6.1% | ||
| Q4 24 | -13837100.0% | 7.4% | ||
| Q3 24 | -1038966.7% | 37.3% | ||
| Q2 24 | -611840.0% | 37.6% | ||
| Q1 24 | -106421.4% | -15.3% |
| Q4 25 | 0.1% | 1.1% | ||
| Q3 25 | 101.1% | 2.6% | ||
| Q2 25 | 440.0% | 2.6% | ||
| Q1 25 | 4507.1% | 1.9% | ||
| Q4 24 | 378600.0% | 5.0% | ||
| Q3 24 | 59266.7% | 1.2% | ||
| Q2 24 | 6980.0% | 1.8% | ||
| Q1 24 | 2535.7% | 1.4% |
| Q4 25 | 1.47× | 46.11× | ||
| Q3 25 | — | 3.27× | ||
| Q2 25 | — | 2.06× | ||
| Q1 25 | — | 2.99× | ||
| Q4 24 | — | 2.16× | ||
| Q3 24 | — | 2.54× | ||
| Q2 24 | — | 9.78× | ||
| Q1 24 | — | -3.35× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FDMT
Segment breakdown not available.
IMAX
| Technology Sales | $46.6M | 37% |
| Image Enhancement And Maintenance Services | $38.1M | 30% |
| Joint Revenue Sharing Arrangement | $20.4M | 16% |
| Maintenance | $16.3M | 13% |
| Finance Income | $2.8M | 2% |
| Other Content Solutions | $1.6M | 1% |
